Androgenetic Alopecia and Metabolic Syndrome: Is Alarin a Missing Link?

J Clin Aesthet Dermatol. 2022 Jul;15(7):32-37.

Abstract

Background: The field of research into the probable link between androgenetic alopecia (AGA) and metabolic syndrome (MetS) is rapidly expanding. The exact underlying pathogenesis yet to be identified. Alarin, a galanin neuropeptide, found to be elevated in patients with metabolic syndrome and may represent a potential link between AGA and MetS.

Objective: The aim of this study was to assess serum levels of alarin in patients with AGA and investigate its possible correlation, if any, with criteria of MetS in those patients.

Methods: The study included 50 male patients with AGA and 30 healthy controls. Weight, height, waist circumference, and body mass index (BMI) were all measured. Systolic and diastolic blood pressure readings were recorded. Serum level of lipids, fasting blood glucose (FBG) and alarin were also assessed.

Results: Anthropometric measures, serum lipids, FBG, and serum alarin were much higher in patients with AGA compared to controls (p<0.05). Forty-one patients with AGA (82%) met the criteria for diagnosis of MetS. Serum level of alarin was significantly higher in those patients and correlated positively with severity and duration of AGA.

Conclusion: Serum level of alarin might represent a potential link between AGA and MetS, opening the door for better understanding of the pathogenesis of both conditions and the possible association between them.

Keywords: Alarin; androgenetic alopecia; metabolic syndrome.